ActoMeg 15 mg+500 mg (Tablet)
Unit Price: ৳ 9.00 (2 x 10: ৳ 180.00)
Strip Price: ৳ 90.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Pioglitazone metformin hydrochloride |
| Company | Unimed unihealth pharmaceuticals ltd |
| Also available as |
Title
- Pioglitazone & Metformin Combination Tablet
Categories
- Medicine
- Diabetes Management
- Oral Hypoglycemic Preparations
Description
- This combination medicine is indicated to improve glycemic control in patients with type 2 diabetes who are already treated with a combination of Pioglitazone and Metformin or whose diabetes is not adequately controlled with Metformin alone.
Dimensions
- Standard tablet size
Color Options
- White
Functions
- Improves glycemic control
- Decreases insulin resistance
- Lowers basal and postprandial plasma glucose
- Enhances insulin sensitivity
- Improves glucose tolerance
Materials
- Pioglitazone
- Metformin hydrochloride
- Inactive ingredients for tablet formulation
Technical Specifications
- Maximum recommended dose of Pioglitazone is 45 mg daily
- Maximum recommended daily dose for Metformin is 2550 mg in adults
- Initial and maintenance dosing should be conservative in patients with advanced age
Design Elements
- Standard tablet form
- Easy-to-swallow
- Film-coated for easier ingestion
Usability Features
- Divided daily doses with meals to reduce gastrointestinal side effects
- Carefully selected dose in patients with advanced age
- Conservative dosing in patients with advanced age
- Store in a cool, dry place
- Protect from light and moisture
Dosage & Administration
- Individualized on effectiveness and tolerability
- Select starting dose based on the patient's current regimen of Pioglitazone and/or Metformin
- Given in divided daily doses with meals to reduce gastrointestinal side effects associated with Metformin
- Starting dose based on the patient's response to current treatments
- Max recommended daily dose of Pioglitazone 45 mg and Metformin 2550 mg
- Careful dosing in special patient populations
Interaction
- May impair vit B12 absorption
- Increased plasma levels with strong CYP2C8 inhibitors (e.g. gemfibrozil)
- Decreased plasma levels with CYP2C8 inducers (e.g. rifampicin)
- Reduced metabolism with cationic drugs eliminated by renal tubular secretion
Contraindications
- Renal disease or dysfunction
- Known hypersensitivity to Pioglitazone, Metformin, or any other component of the combination
- Acute or chronic metabolic acidosis including diabetic ketoacidosis with or without coma
Side Effects
- Upper respiratory tract infection
- Diarrhea
- Peripheral edema
- Headache
Pregnancy & Lactation
- Not well-studied in pregnant women
- Should only be used if potential benefit justifies potential risk to the fetus
- Not recommended for breastfeeding women
Precautions & Warnings
- Should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis
- Caution in combination with insulin, hepatic insufficiency, and heart diseases
- Risk of Metformin accumulation and lactic acidosis with impaired renal function
Use in Special Populations
- Careful dose selection in patients with advanced age
- Monitoring of renal function to prevent Metformin-associated lactic acidosis
- Not to be initiated in patients with clinical evidence of active liver disease
- Liver enzyme monitoring recommended prior to therapy initiation
Overdose Effects
- Appropriate supportive treatment should be initiated according to patient's clinical signs and symptoms
Therapeutic Class
- Oral hypoglycemic preparations
Storage Conditions
- Cool and dry place
- Protect from light and moisture
- Keep out of the reach of children
Other
- Combination of Pioglitazone & Metformin for type 2 diabetes management